Vice President/Senior Vice President, Genomics & Data Science
Stoke Therapeutics
Summary
The VP/SVP, Genomics & Data Science, will serve as a key scientific and strategic leader responsible for integrated Computational, Genomics, and Data systems, Therapeutic Design, and essential support of Discovery, Translational Development, and Technology Innovation. This leader will also oversee the establishment and stewardship of cohesive scientific computation, molecular & genomic data generation, and high-dimensional data interpretation and representation across the R&D organization. Reporting to the Chief Scientific Officer, this executive will grow a high-impact, multi-disciplinary team advancing therapeutic understanding, and partner across the organization to drive therapeutic development and translation, as well as pursue novel and differentiated technologies and scientific opportunities.
Job description
Position Purpose
The VP/SVP, Genomics & Data Science, will serve as a key scientific and strategic leader responsible for integrated Computational, Genomics, and Data systems, Therapeutic Design, and essential support of Discovery, Translational Development, and Technology Innovation. This leader will also oversee the establishment and stewardship of cohesive scientific computation, molecular & genomic data generation, and high-dimensional data interpretation and representation across the R&D organization. Reporting to the Chief Scientific Officer, this executive will grow a high-impact, multi-disciplinary team advancing therapeutic understanding, and partner across the organization to drive therapeutic development and translation, as well as pursue novel and differentiated technologies and scientific opportunities.
Key Responsibilities
- Provide strategic and technical leadership across scientific computation, molecular & genomic functions, and therapeutic design, including organizational management and cross-functional engagement
- Mentor and grow high-performing, technical and scientific team, with an enterprise perspective to data generation and interpretation, collaboration, and efficient execution on priorities
- Champion and oversee scientific computation/AI innovation, including multi-dimensional analytics, data representation & visualization, target insights, integration of genetics and internal/external data, and fit-for-purpose systems
- Lead therapeutic design, including exploration of next-generation approaches
- Establish and drive targeted genomics and molecular assays, including high-throughput approaches, model systems, and biomarker strategies to support development programs at all stages
- Proactively identify external opportunities and collaborations to augment core capabilities
- Champion and represent computational and molecular technologies and capabilities to key internal and external stakeholders, including senior management, board and SAB, through presentation, and publication
Required Skills & Experience
- Minimum 12 years of progressing experience leading quantitatively focused and multidisciplinary teams in the pharmaceutical, biotechnology, or life sciences industry
- Proven track record building and leading high-performing integrated teams, developing talent, and balancing enterprise priorities across efficiency, risk, and innovation
- Extensive experience in computational sciences, bioinformatics, genomic technologies, and related fields – ideally in the context of genetic medicines and therapeutic development
- Ph.D. or equivalent in Computer Science, Genomics, Molecular Biology, or other related quantitative fields
- Proven track record of innovation, strategic thinking, strong problem-solving skills, cross-functional collaboration, data-driven decision making, and organizational skills
- Ability to build and sustain an inclusive, collaborative culture that supports innovation and continuous improvement
- Exceptional communication skills, both verbal and written, with a proven ability to distill technically complex topics to all audiences, present recommendations, and drive alignment with senior leadership and cross-functional stakeholders
- Ability to navigate and influence within a complex matrix organization
Requirements
- Minimum 12 years of progressing experience leading quantitatively focused and multidisciplinary teams in the pharmaceutical, biotechnology, or life sciences industry
- Proven track record building and leading high-performing integrated teams, developing talent, and balancing enterprise priorities across efficiency, risk, and innovation
- Extensive experience in computational sciences, bioinformatics, genomic technologies, and related fields – ideally in the context of genetic medicines and therapeutic development
- Ph.D. or equivalent in Computer Science, Genomics, Molecular Biology, or other related quantitative fields
- Proven track record of innovation, strategic thinking, strong problem-solving skills, cross-functional collaboration, data-driven decision making, and organizational skills
- Ability to build and sustain an inclusive, collaborative culture that supports innovation and continuous improvement
- Exceptional communication skills, both verbal and written, with a proven ability to distill technically complex topics to all audiences, present recommendations, and drive alignment with senior leadership and cross-functional stakeholders
- Ability to navigate and influence within a complex matrix organization
Benefits
- Medical, Dental & Vision
- Life Insurance
- Long-Term Disability Insurance
- Short-Term Disability Insurance
- Paid Parental Leave
- 401(k) Matching
- Unlimited PTO
- Tuition Assistance
- Employee Stock Purchase Program
- Annual Bonus
- Equity Participation
Company overview
Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company dedicated to developing novel RNA-based medicines for severe genetic diseases. Founded in 2014 and headquartered in Bedford, Massachusetts, the company employs its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to create antisense oligonucleotides (ASOs) that selectively restore naturally-occurring protein levels. Stoke's innovative platform focuses on haploinsufficiency diseases where patients have approximately 50% of normal protein levels, primarily targeting conditions affecting the central nervous system and eyes. The company's lead investigational medicine, zorevunersen (STK-001), is currently in Phase 3 clinical trials for Dravet syndrome, a severe form of childhood epilepsy, and has demonstrated promising disease-modifying potential. Stoke also has preclinical programs including STK-002 for autosomal dominant optic atrophy. The company has established strategic collaborations with industry leaders like Biogen for Dravet syndrome development and Acadia Pharmaceuticals for neurodevelopmental disorders. With approximately 51-200 employees, Stoke Therapeutics represents a pioneering force in RNA medicine, aiming to address unmet medical needs in rare genetic diseases through its innovative protein restoration technology.